Session » Vasculitis Poster I: Non-ANCA-Associated and Related Disorders

Date: Sunday, October 21, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 833

11 Patients with Relapsing Polychondritis Presenting with Severe Airways Disease in One Centre in UK

9:00AM-11:00AM: Abstract Number: 825

Assessment of Damage and Prognosis in Patients with Adult IgA Vasculitis: Retrospective Multicentered Cohort Study

9:00AM-11:00AM: Abstract Number: 815

Classic and Atypical Polymyalgia Rheumatica, Are Different Syndromes? Study of 93 Patients with PET/CT from a Single Center

9:00AM-11:00AM: Abstract Number: 834

Clinical Characteristics of IgA Vasculitis in Children and Adults: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 824

Comparing Childhood- Versus Adult-Onset Polyarteritis Nodosa

9:00AM-11:00AM: Abstract Number: 821

Comparison of Aortitis Vs Non-Inflammatory Aortic Aneurysms Among Patients Who Undergo Open Aortic Aneurysm Repair

9:00AM-11:00AM: Abstract Number: 817

Current Diagnostic Delays in Vasculitis and Factors Associated with Time to Diagnosis

9:00AM-11:00AM: Abstract Number: 816

Development of Thoracic Aortic Aneurysms in Patients with Polymyalgia Rheumatica: Underdiagnosed Giant Cell Arteritis?

9:00AM-11:00AM: Abstract Number: 829

DNA Damage and Repair in Patients with Cryoglobulinemic Vasculitis Treated with Direct Anti-HCV Drugs

9:00AM-11:00AM: Abstract Number: 826

Does Anti-Glomerular Basement (anti-GBM) Antibody Positivity Correlate with Relapse in Patients with Anti-GBM Disease?

9:00AM-11:00AM: Abstract Number: 822

Immuno-Inflammatory Markers and MR-Angiographic Imaging to Detect Disease Activity in Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 832

Immunoglobuline a Vasculitis: Comparison between Pediatric and Adult Population

9:00AM-11:00AM: Abstract Number: 820

Incidence And Seasonal Variation Of Biopsy-Proven Giant Cell Arteritis – Revisited: A 20-Year Population-Based Study From Sweden

9:00AM-11:00AM: Abstract Number: 828

Medium and Small-Sized Vessel Involvement in Hypereosinophilic Syndrome

9:00AM-11:00AM: Abstract Number: 831

No More HCV RNA in Serum and Cryoprecipitate in Patients with Persisting HCV-Cryoglobulinemia Vasculitis after Daa-Induced Sustained Virological Response

9:00AM-11:00AM: Abstract Number: 830

Primary Central Nervous System Vasculitis with Tumor-like Presentation

9:00AM-11:00AM: Abstract Number: 827

Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events

9:00AM-11:00AM: Abstract Number: 823

Survival of Biopsy Proven Giant Cell Arteritis in Northern Italy: Correlation with Clinical, Laboratory and Histopathological Findings

9:00AM-11:00AM: Abstract Number: 819

Use of Takayasu Arteritis Damage Score (TADS) to Measure Damage in Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 818

Visual Involvement in Giant Cell Arteritis: A Prospective Multi Center Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].